Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non–small-cell Lung Cancer

Introduction: This study was aimed at clarifying the failure pattern after definitive chemoradiotherapy in patients with stage III non–small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and/or anaplastic lymphoma kinase (ALK) translocation. Conclusions: Although the ALK-positive group showed no characteristic failure pattern, the EGFR-mutant group showed a lower rate of in-field failure and higher rate of out-of-field failure. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2019.02.021

Authors: Masaki Nakamura, Shun-ichiro Kageyama, Seiji Niho, Masayuki Okumura, Hidehiro Hojo, Atsushi Motegi, Naoki Nakamura, Sadamoto Zenda, Kiyotaka Yoh, Koichi Goto, Tetsuo Akimoto